Tirzepatide 60 mg Lap Tested USA

Tirzepatide 60 mg Lap Tested USA — Comprehensive Product Overview Tirzepatide 60 mg is our maximum-strength, laboratory-verified (Lap Tested) research-grade dual GIP/GLP-1 receptor agonist peptide, engineered for the most demanding preclinical research programs — large-animal studies, long-duration chronic efficacy investigations, comprehensive multi-endpoint metabolic phenotyping, high-throughput screening campaigns, and core facility distribution to multiple investigator laboratories. As the highest-capacity format in our Tirzepatide portfolio, the 60 mg vial delivers unmatched research economy for programs operating at maximum scale, while maintaining the rigorous ≥99% HPLC purity specification and expanded analytical testing that characterize our quality commitment. Every 60 mg vial undergoes our “Lap Tested” verification protocol, representing additional in-house analytical confirmation beyond standard batch release testing — ensuring that researchers receive peptide that has been independently verified for identity, purity, and quality. Tirzepatide (CAS: 2023788-19-2, MW: 4813.5 Da) is the 39-amino acid synthetic peptide amide whose dual-receptor pharmacology has established it as the definitive research tool for investigating synergistic GIP/GLP-1 biology. The complete molecular sequence — H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γ-Glu-eicosanedioic acid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 — incorporates the full suite of pharmacological innovations that define Tirzepatide: (1) the native GIP backbone providing the structural template for dual receptor recognition; (2) DPP-4-resistant Aib residues (positions 2, 13) that stabilize the α-helical receptor-binding conformation while blocking N-terminal proteolysis; (3) the C20 eicosanedioic acid fatty diacid moiety at Lys20, conjugated through an optimized AEEA-AEEA-γ-Glu linker system, providing ≥99.5% albumin binding for extended pharmacokinetic half-life; and (4) the imbalanced dual agonism profile — approximately 5-fold GIPR super-agonism relative to native GIP, with balanced GLP-1R agonism comparable to native GLP-1 — that generates the synergistic metabolic effects documented across the preclinical incretin literature. The 60 mg maximum-strength format is purpose-built for research programs operating at the frontier of scale and duration: large rodent cohorts (30-60 animals) for fully powered metabolic phenotyping; long-duration chronic studies (12-24 weeks) investigating metabolic adaptation, durability of effect, and disease modification; large-animal (dog, pig, non-human primate) pharmacokinetic and pharmacodynamic studies requiring proportionally larger peptide quantities; core facility distribution where a single lot serves multiple investigator laboratories with independent experimental protocols; and pharmaceutical discovery programs conducting comprehensive preclinical pharmacology packages. Each vial is produced under ISO-certified quality management systems with expanded analytical documentation. Supplied strictly for research use only (RUO). Key Features 60 mg maximum-strength research vial — the highest-capacity format for large-scale, long-duration, and large-animal preclinical research programs Lap Tested verification — additional in-house analytical confirmation beyond standard batch release testing, providing independent identity, purity, and quality verification Dual GIP and GLP-1 receptor agonist — synergistic dual-incretin mechanism for the most comprehensive metabolic, cardiovascular, and neurological research ≥99% HPLC purity — every batch verified at 214 nm with expanded analytical testing: HPLC, HRMS, MS/MS sequencing, AAA, endotoxin, and residual solvents Lyophilized powder — 24+ month stability at -20°C; premium packaging engineered for long-term storage and frequent laboratory access DPP-4-stabilized peptide engineering — Aib substitutions at positions 2 and 13 for sustained in vivo bioactivity across chronic dosing paradigms Extended-duration albumin-binding pharmacokinetics — C20 diacid moiety enabling flexible dosing schedules from daily to weekly in diverse preclinical species Ideal for large-cohort chronic studies, large-animal pharmacology, core facility distribution, and pharmaceutical R&D programs The Science of Tirzepatide: Pharmacology at Maximum Research Scale At the 60 mg scale, research programs can address the most ambitious questions in dual-incretin pharmacology: Durability and disease modification — does chronic Tirzepatide treatment produce sustained metabolic benefits that persist beyond the active treatment period, or do compensatory mechanisms eventually attenuate the response? Long-duration (12-24 week) studies with comprehensive metabolic phenotyping at multiple time points can distinguish between acute pharmacological effects and genuine disease-modifying outcomes such as reversal of hepatic steatosis, restoration of β-cell function, and permanent resetting of body weight set-point. Species translation — Tirzepatide pharmacology has been most extensively characterized in rodent models, but translation to larger species (dog, pig, NHP) is essential for understanding species-specific differences in receptor pharmacology, pharmacokinetics, and metabolic responses that inform human relevance. Large-animal studies require proportionally larger peptide quantities — precisely the application the 60 mg format is designed to serve. Multi-system pharmacology — beyond canonical metabolic endpoints, chronic Tirzepatide exposure may affect cardiovascular function (blood pressure, heart rate, vascular reactivity, cardiac remodeling), renal function (glomerular filtration, albuminuria, tubulointerstitial fibrosis), neurological function (cognitive performance, neuroinflammation, neuroprotection), and immune function (systemic and tissue-resident immune cell profiles). Comprehensive multi-system phenotyping from a single lot ensures that cross-system correlations reflect true pharmacological relationships rather than lot-specific artifacts. Combination pharmacology — Tirzepatide’s dual mechanism provides a foundation for investigating rational combination strategies: Tirzepatide + amylin analogs (e.g., cagrilintide) for additive appetite suppression; Tirzepatide + FGF21 analogs for enhanced hepatic lipid metabolism; Tirzepatide + SGLT2 inhibitors for complementary glycemic and cardiovascular benefits; and Tirzepatide + MC4R agonists for synergistic CNS-mediated weight loss. These combination studies require substantial quantities of each agent — the 60 mg format ensures adequate Tirzepatide supply. Research Applications Tirzepatide 60 mg supports: Large-cohort chronic rodent studies — 12-24 week treatment in 30-60 DIO mice or 15-30 ZDF rats with comprehensive serial phenotyping; Large-animal pharmacology — pharmacokinetic/pharmacodynamic studies in dog, pig, or NHP models requiring mg/kg dosing and proportionally larger total peptide requirements; Core facility and multi-investigator distribution — centralized procurement and distribution of a single, analytically verified lot across 3-6 investigator laboratories; Comprehensive preclinical pharmacology packages — dose-ranging, chronic efficacy, pharmacokinetic/pharmacodynamic modeling, tissue distribution, metabolite profiling, and preliminary safety pharmacology; Multi-system phenotyping — simultaneous assessment of metabolic, cardiovascular, renal, neurological, and immunological endpoints from a single treatment cohort; Drug combination studies — evaluation of Tirzepatide in rational combination with other pharmacological agents across multiple combination arms; IND-enabling research — comprehensive data packages supporting Investigational New Drug applications and regulatory documentation. Comparative Analysis: Tirzepatide vs. Semaglutide vs. Retatrutide at Maximum Scale In maximum-scale research programs, the choice of incretin peptide investment has major budgetary and scientific implications: Semaglutide — as the GLP-1R-selective standard, Semaglutide is an essential control in all incretin research programs. However, allocating 60 mg quantities to both Semaglutide and Tirzepatide enables the most rigorous head-to-head comparisons: identical lot consistency, matched dosing schedules, parallel experimental timelines, and comprehensive endpoint analysis that can definitively quantify the added value of GIPR co-agonism. At this scale, the scientific return justifies the dual investment. Tirzepatide — the 60 mg maximum-strength format maximizes the scientific output per research dollar for dual-incretin studies. By consolidating GIPR and GLP-1R pharmacology into a single compound, Tirzepatide eliminates the need for separate GIPR and GLP-1R agonist arms, reducing total peptide costs and simplifying experimental logistics. For programs where the primary question concerns dual incretin biology, Tirzepatide 60 mg is the most efficient allocation of research resources. Retatrutide — the triple agonist adds GCGR pharmacology that expands the experimental scope but at the cost of increased complexity and additional endpoints. For programs specifically investigating glucagon biology in the context of incretin co-agonism, Retatrutide is the appropriate tool. For programs focused on the GIP-GLP-1 axis without glucagon variables, Tirzepatide 60 mg provides cleaner data, simpler interpretation, and more efficient resource utilization. Lap Tested Verification Our “Lap Tested” designation for the 60 mg format represents additional in-house analytical verification beyond standard batch release testing. Every Tirzepatide 60 mg vial undergoes: independent HPLC purity verification by a second analyst; confirmatory mass spectrometry on a separate instrument; visual inspection and solubility testing; and documentation review confirming all batch release specifications. This additional verification layer provides researchers with enhanced confidence in the identity, purity, and quality of their research peptide. Disclaimer This product is intended exclusively for laboratory research purposes only. Not FDA-approved for human or veterinary diagnostic, therapeutic, clinical, or prophylactic use. Purchasers must be qualified researchers affiliated with recognized laboratories, universities, biotechnology companies, or research institutions. By purchasing this product, the buyer agrees to use it solely for legitimate scientific research in compliance with all applicable laws, regulations, and institutional guidelines. Product Specifications Product Name: Tirzepatide CAS Number: 2023788-19-2 Molecular Formula: C225H348N48O68 Molecular Weight: 4813.5 Da Sequence: H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γ-Glu-eicosanedioic acid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 Purity: ≥99% (HPLC, 214 nm) Strength: 60 mg per vial Form: Sterile lyophilized powder Grade: Research Use Only (RUO) — Lap Tested Verification: Additional in-house analytical confirmation Solubility: PBS (pH 7.4), 0.1% acetic acid, DMSO, DMF for research applications Storage: Lyophilized: -20°C, desiccated; Reconstituted: aliquot, -20°C or -80°C, avoid freeze-thaw cycles Quality Assurance & Analytical Testing Standard: HPLC (214 nm, ≥99%), ESI-MS (MW ±1.0 Da), AAA, Peptide Content, Endotoxin (LAL), Residual Solvents (GC-HS); Lap Tested enhanced: independent HPLC verification by second analyst, confirmatory MS on separate instrument, solubility and appearance testing, batch documentation review; CoA available upon request with complete analytical data package. Handling & Storage Guidelines Lyophilized: -20°C, desiccated, 24+ months; Reconstitution: sterile PBS pH 7.4 or appropriate vehicle; Post-reconstitution: single-use aliquots, -20°C (4 weeks) or -80°C (6 months); Working solutions: fresh daily from frozen aliquots; Large-format management: consider aliquoting lyophilized powder under dry nitrogen atmosphere into pre-weighed single-use vials for programs requiring frequent small-quantity access over extended periods; this preserves bulk integrity while enabling convenient day-to-day use. USA Shipping & Availability Fast USA domestic shipping — 1-2 business day processing from US fulfillment centers; Cold-chain shipping with insulated packaging and temperature monitoring; Professional discreet laboratory packaging; Available to qualified US research institutions, CROs, and pharmaceutical companies; International shipping for qualified institutions; Maximum-format pricing with volume discounts for multi-vial orders; Institutional supply agreements available — contact our scientific sales team. Why Choose Our Tirzepatide 60 mg Lap Tested? Maximum research capacity — 60 mg supports the largest cohorts, longest durations, and largest species of any Tirzepatide format; Lap Tested verification — additional analytical confirmation providing enhanced confidence in peptide identity, purity, and quality; ≥99% HPLC purity with expanded analytical testing; Dual GIP/GLP-1 mechanism for comprehensive incretin research at maximum scale; Single-lot consistency across massive research programs; Core facility and multi-investigator distribution optimized; Trusted by US pharmaceutical R&D, CROs, academic core facilities, and principal investigators running definitive preclinical programs; Institutional pricing, scheduled delivery, and custom synthesis options available. Advantages and Limitations Advantages: Highest-capacity format for large-scale, long-duration, and large-animal research; Lap Tested verification for enhanced quality confidence; Single-lot homogeneity across comprehensive multi-endpoint, multi-investigator programs; Cost-effective per-mg economics for maximum-scale research; Complete analytical documentation supporting regulatory and publication requirements. Limitations: Not for clinical or therapeutic use; Requires IACUC or equivalent institutional approval for in vivo work; Large format requires disciplined storage and aliquot management; Maximum capacity may exceed requirements for pilot or screening studies — consider smaller formats for initial validation. Frequently Asked Questions (FAQs) Q: Is Tirzepatide 60 mg FDA-approved? A: No. Exclusively for laboratory research use only. Q: Who can purchase? A: Qualified researchers at recognized institutions; institutional verification required. Q: USA shipping? A: Yes, fast domestic shipping from US fulfillment centers. Q: What does “Lap Tested” mean? A: Additional in-house analytical verification beyond standard batch release — independent HPLC, confirmatory MS, solubility testing, and documentation review. Q: Purity specification? A: ≥99% by HPLC at 214 nm, verified for every batch. Q: vs. Semaglutide? A: Tirzepatide is a dual GIP/GLP-1 agonist; Semaglutide is GLP-1R-selective only. The dual mechanism produces synergistic metabolic effects exceeding GLP-1R agonism alone. Q: Suitable for large-animal studies? A: Yes, the 60 mg format is specifically designed to support large-animal (dog, pig, NHP) pharmacology studies requiring proportionally larger peptide quantities. Q: Storage and shelf life? A: Lyophilized: -20°C, 24+ months. Reconstituted: aliquot, -20°C or -80°C, avoid freeze-thaw. Q: Institutional supply agreements available? A: Yes, contact scientific sales for recurring delivery schedules, volume pricing, and custom arrangements. Q: Can this be distributed to multiple investigators? A: Yes, the 60 mg format is optimized for core facility procurement and multi-investigator distribution from a single analytically verified lot. Q: Is additional analytical documentation available? A: Yes, expanded CoA with Lap Tested verification data available upon request. Ordering Information For the Tirzepatide 60 mg Lap Tested maximum-strength format, we recommend direct consultation with our scientific sales team to discuss your research program scale, species, duration, and specific requirements. This ensures optimal format selection, pricing, and delivery scheduling. Visit hkpeptidesworldwide.com or contact our team directly. Institutional purchase orders, credit cards, and wire transfers accepted. HK Peptides Worldwide — powering the most ambitious dual-incretin research programs in the United States.

Related Research & Resources

Resource	Description
Glp 1 Metabolic Peptides Hub	Complete research overview & methodology hub
High Purity Tirzepatide 50Mg	Related research peptide product
Tirzepatide 10 Mg Research Peptide Vials	Related research peptide product
Glp 1 Peptides Metabolic Research	Latest research insights & methodology

View Complete Research Guide »